General Cardiology

Two news anchors sit at a round table in a studio, speaking with a woman in a white coat who appears via video call on a split screen, with "FOX 10 TALKS" branding visible.

A Message From Our Program Leader

Phoenix is a large diverse population with many at-risk and marginalized populations. Our dedicated team of clinician scientists is changing outcomes, driving engagement, and rewriting the future.

Watch Video

About Our Program

The Cardiovascular Research Program is conducting cutting-edge research in new therapies for heart failure, specifically heart failure with preserved ejection fraction. This has historically afflicted far more women than men, including GLP-1, nonsteroidal MRA’s, and innovative use of pulmonary hypertension therapies. We are also participating in novel therapeutics for hereditary forms of high cholesterol, including elevated Lp(a), and patients who are acutely hospitalized with a heart attack, to have optimal cholesterol levels to prevent future recurrence of vascular events. Congenital Heart disease affects 1 out of 100 babies born today. With revolutionary surgical techniques, more than 90% of these survive to adulthood. HonorHealth Research Institute Cardiovascular research is participating in international clinical trials to ensure that these babies will live long and healthy lives, including novel use of SGLT2i therapies.

Cardiovascular Research Facts and Figures

The General Cardiology Research Program has assisted in bringing new innovative therapies for high blood pressure, including new drugs and devices. According to the CDC, high blood pressure continues to affect roughly 37 million Americans.

About 86 million Americans have high cholesterol and nearly 47 million could benefit from cholesterol-modify therapies. The HonorHealth Research Institute has been pivotal in addressing this need for our community.

Congenital Heart Disease impacts 1/100 babies born today and more than 90% survive to adulthood. HonorHealth is participating in pivotal studies to ensure these patients not only survive but thrive with new minimally invasive heart valves, and tailored medication approaches.